OFBiz

Artificial Intelligence in Drug Discovery Market Outlook: Key Trends and Future Prospects

_‹ Previous Topic Next Topic _›

Classic

List

Threaded

1 message

HealthInsights

Artificial Intelligence in Drug Discovery Market Outlook: Key Trends and Future Prospects

Artificial Intelligence in Drug Discovery Market Outlook, Scope & Overview:

Industry reports indicate that the global artificial intelligence (AI) in drug discovery market was valued at USD 1.42 billion in 2023 and is projected to reach USD 11.37 billion by 2031, growing at a CAGR of 29.7% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global AI in Drug Discovery Market

The adoption of AI technologies in drug discovery will continue to influence global market revenues. Pharmaceutical companies and research institutions are increasingly utilizing AI to enhance the efficiency of drug discovery processes, reduce the time and cost associated with drug development, and improve the success rate of new drug candidates.

As a product segment, machine learning algorithms currently hold a significant share of the global AI in drug discovery market. This segment is anticipated to grow at a year-over-year rate of 29.7% in 2024 over 2023 and reach USD 11.37 billion in revenues by 2031. The increasing application of AI in target identification, lead optimization, and clinical trials is expected to drive market growth.

AI in Drug Discovery Solutions – Market Dynamics

Drivers:

AI in drug discovery solutions are witnessing significant growth in the global market due to their ability to analyze large datasets, predict drug-target interactions, and identify potential drug candidates more efficiently than traditional methods. The growing adoption of AI by pharmaceutical companies to accelerate drug development pipelines, coupled with advancements in AI algorithms and computational power, are key factors driving the adoption of AI in drug discovery worldwide. Additionally, the rising prevalence of chronic diseases and the need for personalized medicine are further propelling market growth.

Restraints:

Despite the growth potential, challenges such as data privacy concerns, high implementation costs, and the need for high-quality, annotated datasets are hindering the widespread adoption of AI in drug discovery solutions. Moreover, regulatory uncertainties and the complexity of integrating AI with existing drug discovery workflows pose additional challenges to market expansion.

AI in Drug Discovery Solutions – Market Outlook

The proven benefits of AI in improving the efficiency and success rates of drug discovery processes have contributed to the market's growth. AI in drug discovery solutions are expected to witness increased adoption across major markets, including North America, Europe, and Asia Pacific, driven by advancements in AI technology and the growing focus on precision medicine and personalized healthcare.

Global AI in Drug Discovery Market

The rise in demand for AI in drug discovery solutions in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global AI in drug discovery market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of AI solutions in drug discovery, supported by increasing investments in AI research and development and favorable regulatory frameworks.

Key Players in the AI in Drug Discovery Solutions Market

Leading companies in the AI in drug discovery solutions market include IBM Watson Health, BenevolentAI, Insilico Medicine, and Atomwise, Inc. These companies are at the forefront of developing and commercializing advanced AI platforms for various drug discovery applications, including target identification, lead optimization, and clinical trial design.

In conclusion, the global AI in drug discovery market is poised for substantial growth over the forecast period, driven by technological advancements, increasing healthcare digitization, and the expanding adoption of AI solutions in drug development and personalized medicine.